Zhonghua Xue Ye Xue Za Zhi. 2024 Jul 14;45(7):629-636. doi: 10.3760/cma.j.cn121090-20240528-00194.
Acute lymphoblastic leukemia (ALL) is one of the most common acute leukemias, with rapid onset and progression. The standardized application of chemotherapy and transplantation have improved the prognosis of patients, while the unmet therapeutic needs still exist. Recently novel immunotherapies including Bispecific T cell Engager develop rapidly, offering more options for ALL treatment and also demanding higher requirements for clinical diagnosis and treatment management. Based on the evidence of domestic and international medical evidence and clinical experience, the expert panel updated Chinese consensus for the Bispeific T cell Engager in the treatment of B-cell acute lymphoblastic leukemia (2022) and formulated this edition of the Chinese expert consensus.
急性淋巴细胞白血病（ALL）是最常见的急性白血病之一，起病急、进展快。化疗和移植的规范应用改善了患者预后，但仍存在未被满足的治疗需求。近年来，包括双特异性T细胞衔接器在内的新型免疫疗法发展迅速，为ALL治疗提供了更多选择，同时也对临床诊疗管理提出了更高要求。基于国内外医学证据和临床经验，专家委员会更新了《双特异性T细胞衔接器治疗B细胞急性淋巴细胞白血病中国专家共识（2022年版）》，并制定了本版中国专家共识。
